Multiple myeloma trials in Norway

In Norway 33 Also abroad 704

33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Oslo
Age
18 years and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Oslo, Trondheim
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Loerenskog, Oslo, Stavanger, Trondheim
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Oslo
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Oslo
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637
Phase 1/2Taking people
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Where
Oslo
Age
18 years to 64 years
People
602 worldwide
Run by
AbbVie
See details and how to joinNCT06892522 · EU 2024-515770-27-00
Phase 2/3Taking people
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Where
Oslo
Age
18 years and over
People
680 worldwide
Run by
AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00
No phaseNot yet taking people in Norway
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
Where
Oslo
Age
18 years and over
People
50 worldwide
Run by
Odense University Hospital
See details and how to joinNCT07878208
Phase 1/2Taking people
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Where
Oslo
Age
18 years and over
People
258 worldwide
Run by
Sanofi
See details and how to joinNCT04643002
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Levanger, Loerenskog, Oslo, Trondheim
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Not yet taking people in Norway
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Where
Oslo
Age
18 years and over
People
249 worldwide
Run by
AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00
Phase 3Taking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Oslo, Trondheim
Age
18 years and over
People
1,594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Oslo
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 1/2Taking people
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Where
Oslo, Trondheim
Age
18 years and over
People
62 worldwide
Run by
Celgene
See details and how to joinNCT06988488 · EU 2025-522090-11-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Oslo, Tønsberg
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Bergen, Oslo, Stavanger, Trondheim
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Loerenskog, Oslo, Tonsberg, Trondheim
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 2Not yet taking people in Norway
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
Where
Oslo, Stavanger, Tønsberg, Trondheim
Age
18 years and over
People
50 worldwide
Run by
Odense University Hospital
See details and how to joinNCT07757412 · EU 2025-522114-23-00
Phase 3Taking people
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Where
Oslo
Age
18 years and over
People
153 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00
Phase 2Taking people
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Where
Oslo
Age
18 years and over
People
105 worldwide
Run by
European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00
Phase 3Not yet taking people in Norway
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Bergen
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
No phaseTaking people
The Norwegian Immunotherapy in Multiple Myeloma Study
Where
Ålesund, Arendal, Bærum, Bergen, Bodø, Drammen, Førde, Gjøvik, Haugesund, Kristiansand, Kristiansund, Levanger, Molde, Nordbyhagen, Oslo, Skien, Stavanger, Tønsberg, Tromsø, Trondheim, Volda
Age
18 years and over
People
400
Run by
St. Olavs Hospital
See details and how to joinNCT06855121
Phase 1Taking people
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Oslo
Age
18 years and over
People
135 worldwide
Run by
AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Aalesund, Bergen, Lørenskog, Oslo
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 2Taking people
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Where
Oslo, Toensberg
Age
18 years and over
People
150 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT07107529 · EU 2024-520433-76-00